These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Inhibitors of prostaglandin synthesis during pregnancy. 1. Embryopathic activity of indomethacin in mice. Persaud TV; Moore KL Anat Anz; 1974; 136(4):349-53. PubMed ID: 4460761 [No Abstract] [Full Text] [Related]
64. Opioid receptor approaches for the development of medications for pregnant women. Szeto HH NIDA Res Monogr; 1995; 149():100-15. PubMed ID: 8775837 [TBL] [Abstract][Full Text] [Related]
65. Clinical aspects of developmental pharmacology and toxicology. Aranda JV; Stern L Pharmacol Ther; 1983; 20(1):1-51. PubMed ID: 6353435 [No Abstract] [Full Text] [Related]
67. [Experimental study of cardiotoxic effect of the pesticide sulfocarbathione]. Gadalina ID; Mikhaĭlova OG; Vendilo MV Gig Sanit; 1990 Nov; (11):35-8. PubMed ID: 2093584 [TBL] [Abstract][Full Text] [Related]
68. Placental transfer of drugs. Chamberlain G Clin Exp Obstet Gynecol; 1986; 13(3-4):107-12. PubMed ID: 3536179 [No Abstract] [Full Text] [Related]
69. [Effects of maternal methadone addiction on the growth and health of the fetus]. Rosati P; De Santis M; Noia G; Bellati U; Mancuso S Minerva Ginecol; 1988 Oct; 40(10):597-601. PubMed ID: 3222002 [No Abstract] [Full Text] [Related]
70. Physiological changes during pregnancy and their implications for pharmacological treatment. Redmond GP Clin Invest Med; 1985; 8(4):317-22. PubMed ID: 4075616 [TBL] [Abstract][Full Text] [Related]
71. Maternal drug exposure and perinatal intracranial hemorrhage. Soller RW; Stander H Obstet Gynecol; 1981 Dec; 58(6):735-40. PubMed ID: 7312240 [No Abstract] [Full Text] [Related]
72. [Characteristics of the examination and drug therapy of pregnant women suffering from cardiovascular diseases]. Eliseev OM Ter Arkh; 1988; 60(10):33-7. PubMed ID: 3222746 [No Abstract] [Full Text] [Related]
74. THE EFFECTS ON THE FETUS OF DRUGS GIVEN DURING PREGNANCY. MEESTER WD Marquette Med Rev; 1964 Nov; 30():147-54. PubMed ID: 14227526 [No Abstract] [Full Text] [Related]
76. Drugs in feto maternal medicine. Tambyraja RL Ann Acad Med Singap; 1987 Apr; 16(2):281-5. PubMed ID: 3318658 [TBL] [Abstract][Full Text] [Related]
77. Fetal and perinatal exposure to drugs and chemicals: novel biomarkers of risk. Etwel F; Hutson JR; Madadi P; Gareri J; Koren G Annu Rev Pharmacol Toxicol; 2014; 54():295-315. PubMed ID: 24160701 [TBL] [Abstract][Full Text] [Related]
78. Etretinate embryotoxicity 7 months after discontinuation of treatment. Verloes A; Dodinval P; Koulischer L; Lambotte R; Bonnivert J Am J Med Genet; 1990 Nov; 37(3):437-8. PubMed ID: 2260582 [No Abstract] [Full Text] [Related]
79. Effect of maternal inhalation of 10 oxygen upon the human fetus. Wood C; Hammond J; Lumley J; Newman W Aust N Z J Obstet Gynaecol; 1971 May; 11(2):85-90. PubMed ID: 5284377 [No Abstract] [Full Text] [Related]
80. Exposure to chemical carcinogens during pregnancy: consequences for mother and conceptus. Rice JM Adv Exp Med Biol; 1984; 176():13-49. PubMed ID: 6388255 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]